reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
RGLD ROYAL GOLD INC
URI UNITED RENTALS INC.
DOV DOVER CORPORATION
MTH MERITAGE HOMES CORPORATION
MRK MERCK & CO. INC.
FORM FORMFACTOR INC.
CPF CENTRAL PACIFIC FINANCIAL CORP.
CHDN CHURCHILL DOWNS INCORPORATED
AR ANTERO RESOURCES CORPORATION
UVSP UNIVEST FINANCIAL CORPORATION
VIRT VIRTU FINANCIAL INC. CLASS A
NOC NORTHROP GRUMMAN CORPORATION
CECE CECO ENVIRONMENTAL CORP.
CMG CHIPOTLE MEXICAN GRILL INC.
PI IMPINJ INC.
MRUS MERUS B V
ADES ADVANCED EMISSIONS SOLUTIONS
HCC WARRIOR MET COAL INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
KDP KEURIG DR PEPPER INC.
MMMB MAMAMANCINI'S HOLDINGS INC
FXI ISHARES CHINA LARGE-CAP ETF
STRA STRATEGIC EDUCATION INC.
DELL DELL TECHNOLOGIES INC CLASS C
TNK TEEKAY TANKERS
AIMD.P AIM4 VENTURES
ALXO ALX ONCOLOGY HOLDINGS
CSU CAPITAL SENIOR LIVING
LRN STRIDE INC
VRT VERTIV HOLDINGS CO (A)
AMR ALPHA METALLURGICAL RESOURCES INC
RSVR RESERVOIR MEDIA
CADL INC.
SG CANDEL THERAPEUTICS INC
EEMA SWEETGREEN INC
CASH ONTO INNOVATION INC.
FEBO ISHARES MSCI EMERGING MARKETS ASIA INDEX
METC HORIZONS HIGH INTEREST SAVINGS ETF
PROP FENBO HOLDINGS LIMITED
AESI RAMACO RESOURCES INC.
PRAIRIE OPERATING CO.
ATLAS ENERGY SOLUTIONS INC CL A
FirstCash Reports Record First Quarter Results; Earnings per Share Inc...
FirstCash Reports Record First Quarter Results; Earnings per Share Increase 32% in Total and 24% on an Adjusted Basis; Announces Acquisitions of 22 U.S. Pawn Stores and 19 New Store Openings in LatAm; Declares Quarterly Cash Dividend FORT WORTH, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- FirstCash Holdings, Inc. (“FirstCash” or the “Company”) (Nasdaq: FCFS), the leading international operator of more than 3,000 retail pawn stores and a leading provider of retail point-of-sale (“POS”) payment solutions through American First Finance (“AFF”), today announced operating results for the three m...
Cue Biopharma to Present at the 2024 American Society of Clinical Onco...
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-based biologics,...
Royal Gold Provides 2024 Guidance for Sales, DD&A and Effective Tax Ra...
DENVER--(BUSINESS WIRE)-- Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold” or the “Company,” “we” or “our”) announced today its guidance for calendar year 2024 total stream and royalty sales volume, depletion, depreciation and amortization expense (“DD&A”), and effective tax rate, as well as an update on the recent repayment of outstanding borrowings. 2024 Guidance Sales guidance for 2024 is provided on a sales volume basis to improve transparency and avoid the effect of volatile commodity prices in the conversion of revenue to gold equivalent ounces. Sales vol...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
The Pullback Finally Begins; Testing 2-Month Supports We have discussed for months that we will need to see the S&P 500 and Nasdaq 100 (QQQ) close below their 20-day MAs/21-day EMAs for more than 2-3 consecutive days in order to get more cautious. While this has not happened yet (only two consecutive days so far, yesterday and Friday), it does appear to be going in that direction as the U.S. dollar (DXY) climbs to test major $106 resistance, and amid 10- and 30-year Treasury yields breaking abo...
WM WASTE MANAGEMENT INC.
SCCO SOUTHERN COPPER CORPORATION
NGD. NEW GOLD INC.
FCX FREEPORT-MCMORAN INC.
AGI. ALAMOS GOLD INC.
TKO. TASEKO MINES LIMITED
EGO ELDORADO GOLD CORP.
K. KINROSS GOLD CORPORATION
IMG. IAMGOLD CORPORATION
JAGGF JAGUAR MINING INC.
SEA SEABRIDGE GOLD
TECK.B TECK RESOURCES LIMITED CLASS B
RSG REPUBLIC SERVICES INC.
BVN... COMPANIA DE MINAS BUENAVENTURA SAA SPONSORED ADR
WCN WASTE CONNECTIONS INC.
MUX MCEWEN MINING INC.
Royal Gold Provides Update on Q1 2024 Stream Segment Sales and Details...
DENVER--(BUSINESS WIRE)-- Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold” or the “Company,” “we” or “our”) announced today that its wholly owned subsidiary, RGLD Gold AG, sold approximately 49,500 gold equivalent ounces (GEOs)1 comprised of approximately 38,100 ounces of gold, 635,000 ounces of silver and 1,100 tonnes of copper related to its streaming agreements during the three-month period ended March 31, 2024 (the “first quarter”). The Company had approximately 16,800 ounces of gold, 349,400 ounces of silver, and 400 tonnes of copper in inventory at March 31, ...
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Resu...
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results. Presented additional positive data from the ongoing Phase 1 trials of CUE-101 in first line (1L) human papillomavirus positive (HPV+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in combinatio...
Royal Gold Announces Investor Update on Wednesday, April 17, 2024
DENVER--(BUSINESS WIRE)-- Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold” or the “Company,” “we” or “our”) announced today that management will host an Investor Update to provide an update on Royal Gold’s business, including 2024 guidance, on Wednesday, April 17, 2024 from 10:00 a.m. to noon EDT (8:00 a.m. to 10:00 a.m. MDT). A press release detailing 2024 guidance will be issued, before market open, on the same day. Prepared remarks by members of Royal Gold’s management team will be followed by a live question and answer session. Access to the live event will b...
Royal Gold Presenting at the Gold Forum Europe 2024 Conference
DENVER--(BUSINESS WIRE)-- Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold” or the “Company,” “we” or “our”) announced today that management will present at the Gold Forum Europe 2024 conference in Zurich, Switzerland. Dan Breeze, Senior Vice President, Corporate Development, RGLD Gold AG, will address conference participants on Tuesday, April 9, at 10:30 a.m. CET (4:30 a.m. EDT; 2:30 a.m. MDT) in a presentation lasting 20 minutes. The presentation will be live streamed and will be available for on-demand streaming starting on April 12 at 6:00 p.m. CET (Noon EDT; 10...
Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma to Host Business Update Call and Webcast BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s . The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology progr...
- Valens Research
CNC - Valens Credit Report - 2024 03 13
Cash bond markets are overstating CNC's credit risk with a YTW of 5.617% relative to an Intrinsic YTW of 4.827%, while CDS markets are slightly overstating credit risk with a CDS of 126bps relative to an Intrinsic CDS of 69bps. Furthermore, Moody's is overstating CNC's fundamental credit risk with its Ba1 credit rating three notches below Valens' IG4+ (Baa1) credit rating. Incentives Dictate Behavior™ analysis highlights mixed signals for credit holders. As positives, most management members ar...
Firstcash Holdings Inc: 1 director
A director at Firstcash Holdings Inc sold 57,640 shares at 118.810USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
- Valens Research
Valens Equity Weekly Insights - 2024 03 12
Centene (CNC) is the largest managed health care provider for Medicaid and one of the top providers for Medicare as well with over 26 million members across all of its services. Uniform Accounting highlights that the market is overly pessimistic given exaggerated fears surrounding government spending, suggesting the potential for equity upside. Centene is one of the largest managed care organizations (“MCO”) in the United States. The company provides healthcare services to nearly one in 15...
Amphastar Pharmaceuticals Inc: 1 director
A director at Amphastar Pharmaceuticals Inc sold 12,500 shares at 47.178USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Royal Gold to Participate in the Renmark Financial Communications Virt...
DENVER--(BUSINESS WIRE)-- Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold” or the “Company,” “we” or “our”) announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Alistair Baker, Vice President Investor Relations and Business Development, will present on Wednesday, March 13 at 12:00 p.m. EDT (11:00 a.m. CDT / 10:00 a.m. MDT), and access to a replay of the event will be available on our website the week of March 18 or may be accessed on the Renmark Financial Communications Inc. websit...
Gilead Sciences Inc: 1 director
A director at Gilead Sciences Inc sold 10,230 shares at 72.823USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Royal Gold Announces Second Quarter Dividend
DENVER--(BUSINESS WIRE)-- Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold” or the “Company,” “we” or “our”) announced today that its Board of Directors has declared its second quarter dividend of $0.40 per share of common stock. The dividend is payable on Friday, April 19, 2024, to shareholders of record at the close of business on Friday, April 5, 2024. Corporate Profile Royal Gold is a precious metals stream and royalty company engaged in the acquisition and management of precious metal streams, royalties and similar production-based interests. As of December...
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 20...
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company’s lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexander Dimitrios Colevas, M.D., a principal investigator at Stanford University participating i...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.